Literature DB >> 19819973

Neurogenin 3-specific dipeptidyl peptidase-2 deficiency causes impaired glucose tolerance, insulin resistance, and visceral obesity.

Olga V Danilova1, Albert K Tai, Deanna A Mele, Martin Beinborn, Andrew B Leiter, Andrew S Greenberg, James W Perfield, Jason Defuria, Praful S Singru, Ronald M Lechan, Brigitte T Huber.   

Abstract

The control of glucose metabolism is a complex process, and dysregulation at any level can cause impaired glucose tolerance and insulin resistance. These two defects are well-known characteristics associated with obesity and onset of type 2 diabetes. Here we introduce the N-terminal dipeptidase, DPP2, as a novel regulator of the glucose metabolism. We generated mice with a neurogenin 3 (NGN3)-specific DPP2 knockdown (kd) to explore a possible role of DPP2 in maintaining metabolic homeostasis. These mice spontaneously developed hyperinsulinemia, glucose intolerance, and insulin resistance by 4 months of age. In addition, we observed an increase in food intake in DPP2 kd mice, which was associated with a significant increase in adipose tissue mass and enhanced liver steatosis but no difference in body weight. In accordance with these findings, the mutant mice had a higher rate of respiratory exchange than the control littermates. This phenotype was exacerbated with age and when challenged with a high-fat diet. We report, for the first time, that DPP2 enzyme activity is essential for preventing hyperinsulinemia and maintaining glucose homeostasis. Interestingly, the phenotype of NGN3-DPP2 kd mice is opposite that of DPP4 knockout mice with regard to glucose metabolism, namely the former have normal glucagon-like peptide 1 levels but present with glucose intolerance, whereas the latter have increased glucagon-like peptide 1, which is accompanied by augmented glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19819973      PMCID: PMC2795711          DOI: 10.1210/en.2009-0386

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  38 in total

Review 1.  Speed congenics: a classic technique in the fast lane (relatively speaking).

Authors:  E Wakeland; L Morel; K Achey; M Yui; J Longmate
Journal:  Immunol Today       Date:  1997-10

Review 2.  Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.

Authors:  Laurie L Baggio; Daniel J Drucker
Journal:  Treat Endocrinol       Date:  2002

3.  Central relaxin-3 administration causes hyperphagia in male Wistar rats.

Authors:  B M C McGowan; S A Stanley; K L Smith; N E White; M M Connolly; E L Thompson; J V Gardiner; K G Murphy; M A Ghatei; S R Bloom
Journal:  Endocrinology       Date:  2005-04-21       Impact factor: 4.736

4.  A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness.

Authors:  Martin Beinborn; Christine I Worrall; Edward W McBride; Alan S Kopin
Journal:  Regul Pept       Date:  2005-08-15

5.  Ménétrier's disease in a patient with Helicobacter pylori infection is linked to elevated glucagon-like peptide-2 activity.

Authors:  Kazuhiro Watanabe; Martin Beinborn; Shinya Nagamatsu; Hitoshi Ishida; Shin'ichi Takahashi
Journal:  Scand J Gastroenterol       Date:  2005-04       Impact factor: 2.423

6.  Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7).

Authors:  Marie-Berthe Maes; Anne-Marie Lambeir; Kambiz Gilany; Kristel Senten; Pieter Van der Veken; Barbara Leiting; Koen Augustyns; Simon Scharpé; Ingrid De Meester
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

Review 7.  Molecular mediators of hepatic steatosis and liver injury.

Authors:  Jeffrey D Browning; Jay D Horton
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.

Authors:  R Mentlein; B Gallwitz; W E Schmidt
Journal:  Eur J Biochem       Date:  1993-06-15

9.  Cre-lox-regulated conditional RNA interference from transgenes.

Authors:  Andrea Ventura; Alexander Meissner; Christopher P Dillon; Michael McManus; Phillip A Sharp; Luk Van Parijs; Rudolf Jaenisch; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

10.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Authors:  C F Deacon; A H Johnsen; J J Holst
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958

View more
  5 in total

Review 1.  The metabolic serine hydrolases and their functions in mammalian physiology and disease.

Authors:  Jonathan Z Long; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2011-06-23       Impact factor: 60.622

2.  Extended lifespan and reduced adiposity in mice lacking the FAT10 gene.

Authors:  Allon Canaan; Jason DeFuria; Eddie Perelman; Vincent Schultz; Montrell Seay; David Tuck; Richard A Flavell; Michael P Snyder; Martin S Obin; Sherman M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-24       Impact factor: 11.205

3.  S28 peptidases: lessons from a seemingly 'dysfunctional' family of two.

Authors:  John W Kozarich
Journal:  BMC Biol       Date:  2010-06-28       Impact factor: 7.431

Review 4.  Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.

Authors:  L Wagner; C Klemann; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-03-02       Impact factor: 4.330

5.  Structures of human DPP7 reveal the molecular basis of specific inhibition and the architectural diversity of proline-specific peptidases.

Authors:  Gustavo Arruda Bezerra; Elena Dobrovetsky; Aiping Dong; Almagul Seitova; Lissete Crombett; Lisa M Shewchuk; Annie M Hassell; Sharon M Sweitzer; Thomas D Sweitzer; Patrick J McDevitt; Kyung O Johanson; Karen M Kennedy-Wilson; Doug Cossar; Alexey Bochkarev; Karl Gruber; Sirano Dhe-Paganon
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.